Quantcast

Latest Affymax Inc. Stories

2011-01-14 08:30:00

VANCOUVER, Canada, Jan. 14, 2011 /PRNewswire-Asia/ -- Insiderslab.com caught up the convincing insiders trading today for the following companies: Apple, Applied Materials, Unitedhealth, SanDisk, Broadcom, & Affymax. No needs to attend the board minutes, individual investors now have a chance to trade even better than those insiders. Insider's buy and sell is a valuable screen to help investors determine which stock to track further. Academic evidence indicates that corporate...

2010-07-21 09:00:00

VANCOUVER, Canada, July 21 /PRNewswire-Asia/ -- Today Insiderslab.com issues new research reports on large insider trades found in the above Blue Chips or Penny Stock companies. Insiders refer to company C-Level Officers (CEOs, CFOs, COOs) and Directors who are involved in making critical corporate decisions. There are thousands of insider filings on the stock markets every day. Insiderslab.com strives to turn this massive raw data into usable information that investors can use to do...

2008-11-13 09:00:37

Affymax, Inc. (Nasdaq:AFFY) today announced that enrollment has been completed in EMERALD 1, one of its Phase 3 clinical trials of its lead investigational therapy, Hematide(TM), which is being evaluated for the treatment of anemia in chronic renal failure patients. EMERALD 1 includes over 800 dialysis patients from over 90 sites in the United States. "With our non-dialysis trials, PEARL 1 and 2, as well as our dialysis trial, EMERALD 1, fully enrolled, we have now completed enrollment in...

2008-11-06 11:17:54

Affymax, Inc. (Nasdaq: AFFY) today announced at the American Society of Nephrology Renal Week 2008 in Philadelphia positive results from a long-term safety and effectiveness study of its lead investigational therapy, Hematide(TM), which is being evaluated for the treatment of anemia in chronic renal failure patients. In the Phase 2 study analysis presented by Iain Macdougall, M.D., Hematide clinical investigator and honorary senior lecturer at King's College Hospital in London, 182 patients...

2008-11-03 09:00:40

Affymax, Inc. (Nasdaq:AFFY) today announced that enrollment has been completed in the second of four Phase 3 clinical trials of its lead investigational therapy, Hematide(TM), which is being evaluated for the treatment of anemia in chronic renal failure patients. PEARL 2 (Phase 3 Evaluation of Hematide for Anemia Correction in Chronic Renal Failure) is fully enrolled with over 490 non-dialysis patients from over 60 sites in the United States and Europe. "With PEARL 2 fully enrolled, we have...


Word of the Day
kenspeckle
  • Having so marked an appearance as easily to be recognized.
This word may come from the Swedish 'kanspak,' quick at recognizing persons or things, or else from confusion with 'conspicuous.'